Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481570 | 0.86 | NOTUM (0.49) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL21849284 | 0.84 | NOTUM (0.47) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL11605245 | 0.81 | RXRA (0.50) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL23975942 | 0.81 | NOTUM (0.52) | NOTUMSMN1; SMN2CYP3A4CYP2C9MGLL | |
| SCHEMBL30225224 | 0.81 | NOTUM (0.52) | NOTUMSMN1; SMN2CYP3A4CYP2C9MGLL | |
| SCHEMBL19402280 | 0.80 | NOTUM (0.47) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL4886069 | 0.80 | MAPT (0.47) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL21776830 | 0.79 | NOTUM (0.52) | NOTUM | |
| SCHEMBL10361336 | 0.79 | NOTUM (0.47) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL5481442 | 0.76 | NOTUM (0.40) | NOTUMSMN1; SMN2ALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-25 | — | — | US | disclosed |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-25 | — | — | US | disclosed |
| US-20210179590-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210179590-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-3700899-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | disclosed |
| CN-101018779-A | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | CN | disclosed |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1720860-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | disclosed |
| WO-2005080379-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179590-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | GLS, TNNI3, CYP11B2 | NOTUM 2750/4885SMN1; SMN2 4627/4885ALDH1A1 858/4885 |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | NOTUM 2750/4885SMN1; SMN2 4627/4885ALDH1A1 858/4885 |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRIN3A, GRM1 | NOTUM 4056/4885SMN1; SMN2 4254/4885ALDH1A1 3228/4885 |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | NOTUM 4132/4885SMN1; SMN2 2393/4885ALDH1A1 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.